Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Shannon Breen"'
Autor:
Mark Cobbold, Nicolas Giraldo, Gordon Moody, Allison Barrett, Jean-Martin Lapointe, Shannon Breen, Rosa Carrasco, Zachary Britton, Benjamin Clark, Maria AS Broggi, Bala NN Rao Attili, Amy Hatke, Christina Grigoriadou, Melissa Damschroder, Emily Bosco
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/50476fa3ecc7484c87ae588263230680
Autor:
Gordon Moody, Letizia Giardino, Allison Barrett, Ping-Hsien Lee, Shannon Breen, Ashley Merlino, Lorenzo Ortiz, Rosa Carrasco
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0311a467531d46c188c3c4ff6cdf92ea
Autor:
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M. Pezold, John Meekin, Chien-ying Chang, Rosa A. Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier, Benjamin Clark, Nina J. Chu, Alessio Vantellini, Philip L. Martin, Clare E. Hoover, Kenesha Riley, Steve M. Sweet, David Chain, Yeoun Jin Kim, Eric Tu, Nathalie Harder, Sandrina Phipps, Melissa Damschroder, Ryan N. Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Prostate cancer is generally considered an immunologically “cold” tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to “heat up” the tu
Externí odkaz:
https://doaj.org/article/e772d4b790a848fcb94aa4259efad645
Autor:
R. James Christie, Arnaud C. Tiberghien, Qun Du, Binyam Bezabeh, Ryan Fleming, Amanda Shannon, Shenlan Mao, Shannon Breen, Jing Zhang, Haihong Zhong, Jay Harper, Herren Wu, Philip W. Howard, Changshou Gao
Publikováno v:
Antibodies, Vol 6, Iss 4, p 20 (2017)
Thiosuccinimide-linked antibody-drug conjugates (ADCs) are susceptible to drug loss over time due to a retro-Michael reaction, which can be prevented by selecting stable conjugation positions or hydrolysis of the thiosuccinimide. Here, we investigate
Externí odkaz:
https://doaj.org/article/d8a3eda79f854774ad8483d0cf099f77
Autor:
Adeela Kamal, Ronald Herbst, Robert E. Hollingsworth, David A. Tice, Philip W. Howard, Keven Huang, Mary Jane Hinrichs, Elaine M. Hurt, Haihong Zhong, Marlon Rebelatto, Sanjoo Jalla, Lilian van Vlerken-Ysla, Shannon Breen, Leslie Wetzel, Cui Chen, Linda Xu, Patrick Strout, Martin Korade, Allison M. Marrero, Shenlan Mao, Francois D'Hooge, Ryan Fleming, Jelena Jovanovic, David Bannister, Leeanne Lewis, Rose Marwood, Dorin Toader, Nazzareno Dimasi, Christopher Lloyd, Jay Harper
Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PBD and 5T4-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de526dbdf0be492e85149344521acac5
https://doi.org/10.1158/1535-7163.22508511
https://doi.org/10.1158/1535-7163.22508511
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse. We developed a novel antibody–drug conjugate (ADC) targeting CS-1, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063a7b8839eda8429b31260763a0368a
https://doi.org/10.1158/1535-7163.c.6542664
https://doi.org/10.1158/1535-7163.c.6542664
Autor:
David A. Tice, Ronald Herbst, Andrew J. Pierce, Jay Harper, Rajiv Raja, Nicholas Holoweckyj, Brandon W. Higgs, James Conway, Maureen Kennedy, Christine Fazenbaker, Jing Zhang, Shannon Breen, Ravinder Tammali, Cui Chen, Haihong Zhong
Supplemental Figure S1: Knockdown of BRCA1 or BRCA2 sensitizes Hela cells to PBD payload and PBD-based ADC in vitro. Supplemental Figure S2: Genetic deletion of BRCA1 sensitizes cells to PBD-based ADC. Supplemental Table S1: BRCA mutation(s) in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287f5a606ce990a7e443afbe48eb07df
https://doi.org/10.1158/1535-7163.22510440
https://doi.org/10.1158/1535-7163.22510440
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Supplementary Materials and Methods, Supplementary Table S1. Sources of cell lines and cell growth media; Supplemental Table S2. Sources of antibodies for flow cytometry; Supplementary Table S3. CS-1 ADC Characteristics, Supplemental Table S4. Pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62318dd34971780d373a1e55ed154426
https://doi.org/10.1158/1535-7163.22520520.v1
https://doi.org/10.1158/1535-7163.22520520.v1
Autor:
Robert E. Hollingsworth, Yihong Yao, Christopher Morehouse, Jiaqi Huang, Cui Chen, Shannon Breen, Christine Fazenbaker, Haihong Zhong
Supplementary Data. Supplemental Table S1: Summary of MEDI-573 IC50 on the proliferation of sarcoma cell lines with or without exogenously added IGF-1 or IGF-2. Supplemental Figure S1: Effect of MEDI-573 in combination with AZD2014 on SJSA-1 tumor gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a81eb21c443bea3159101d3f4e9896e
https://doi.org/10.1158/1535-7163.22502716.v1
https://doi.org/10.1158/1535-7163.22502716.v1
Autor:
Robert E. Hollingsworth, Yihong Yao, Christopher Morehouse, Jiaqi Huang, Cui Chen, Shannon Breen, Christine Fazenbaker, Haihong Zhong
MEDI-573 is a human antibody that neutralizes insulin-like growth factor (IGF) I and IGFII. IGFs are overexpressed in multiple types of cancer; their overexpression is a potential mechanism for resistance to IGFI receptor (IGFIR)-targeting therapy. E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8b2cc4af6799d7f472c16a2214e150
https://doi.org/10.1158/1535-7163.c.6537154.v1
https://doi.org/10.1158/1535-7163.c.6537154.v1